Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
VBI Vaccines Inc. VBIV
$2.86
-$0.26 (-8.92%)
На 18:00, 12 мая 2023
+74.83%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
26772559.00000000
-
week52high
40.50
-
week52low
2.35
-
Revenue
1082000
-
P/E TTM
-5
-
Beta
1.84982600
-
EPS
-13.34000000
-
Last Dividend
1.25000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Strong Buy | Strong Buy | 09 авг 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 08 мар 2022 г. |
| Raymond James | Strong Buy | Outperform | 27 авг 2020 г. |
| Raymond James | Outperform | Outperform | 22 июл 2020 г. |
| Raymond James | Outperform | 14 ноя 2019 г. | |
| Raymond James | Outperform | Strong Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mazaltov Avi | A | 75000 | 75000 | 26 янв 2023 г. |
| DeWilde Michel | A | 50000 | 50000 | 26 янв 2023 г. |
| McKee Blaine H. | A | 50000 | 50000 | 26 янв 2023 г. |
| McNulty Christopher | A | 75000 | 75000 | 26 янв 2023 г. |
| Beattie Nell | A | 75000 | 75000 | 26 янв 2023 г. |
| Diaz-Mitoma Francisco | A | 75000 | 75000 | 26 янв 2023 г. |
| Anderson David Evander | A | 75000 | 75000 | 26 янв 2023 г. |
| Braga Damian | A | 50000 | 50000 | 26 янв 2023 г. |
| Baxter Jeff | A | 100000 | 100000 | 26 янв 2023 г. |
| Dillman John Robert | A | 75000 | 75000 | 26 янв 2023 г. |
Новостная лента
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
Zacks Investment Research
05 апр 2023 г. в 12:56
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
Market Watch
04 апр 2023 г. в 08:14
VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
13 мар 2023 г. в 10:44
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
Zacks Investment Research
13 окт 2022 г. в 12:48
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
Seeking Alpha
22 сент 2022 г. в 10:42
VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare "Bio Boom" speculative portfolio. The company's efforts in 2022 have fortified that position.